Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-31

Study Completion Date

2019-04-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with Psoriasis in Korea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645814

Psoriasis

COMPLETED PHASE2

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment

NCT01316224

Psoriasis Psoriatic Arthritis

COMPLETED

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00195676

Psoriasis

COMPLETED PHASE3

A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

NCT03236870

Psoriasis

COMPLETED

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00646191

Psoriasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants receiving adalimumab

Participants with Psoriasis receiving adalimumab

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant has a diagnosis of Psoriasis by investigator.
* Participant (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label.
* Participant must be able and willing to provide written informed consent and comply with the requirements of this study protocol.

Exclusion Criteria

* Participants who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks.
* Participation in any Psoriasis-related clinical trial at the time of enrolment, at baseline or at any point during the study period.
* Participants, who in the investigator's view, may not be able to accurately report their questionnaires

Minimum Eligible Age

19 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No